Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma

Interventions: Drug: pembrolizumab
Drug: gemcitabine
Drug: vinorelbine
Drug: liposomal doxorubicin
Procedure: Stem cell mobilization and collection

First Posted Date: 2018-08-07

Last Posted Date: 2025-06-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 257

Registration Number: NCT03618550

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations

Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: SAE battery
Behavioral: Assessments

First Posted Date: 2018-08-07

Last Posted Date: 2025-01-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 187

Registration Number: NCT03619083

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Phase 1

Active, not recruiting

Conditions: Upper Tract Urothelial Carcinoma

Interventions: Drug: WST11 mediated vascular targeted phototherapy (VTP)
Procedure: Endoscopy

First Posted Date: 2018-08-06

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03617003

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

Conditions: Non-Malignant Hematologic Disorders

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Clofarabine
Drug: Fludarabine
Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Procedure: CliniMACS reagents

First Posted Date: 2018-08-03

Last Posted Date: 2021-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03615144

Locations: 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2025-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors

Not Applicable

Active, not recruiting

Conditions: Brain Tumor

Interventions: Device: fMRI Paradigms

First Posted Date: 2018-07-27

Last Posted Date: 2025-01-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT03604302

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Fanconi Anemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Anti-Thymocyte Globulin (Rabbit)
Device: The CliniMACS device
Drug: G-CSF

First Posted Date: 2018-07-26

Last Posted Date: 2022-04-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03600909

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2

Recruiting

Conditions: Sezary Syndrome
Mycosis Fungoides
Lymphomatoid Papulosis

Interventions: Drug: brentuximab vedotin

First Posted Date: 2018-07-16

Last Posted Date: 2025-04-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT03587844

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Phase 1

Active, not recruiting

Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Interventions: Drug: Ibrutinib
Drug: Copanlisib

First Posted Date: 2018-07-10

Last Posted Date: 2024-02-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT03581942

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel 60 mg/m2
Drug: Docetaxel 75 mg/m2
Drug: Radium-223

First Posted Date: 2018-07-02

Last Posted Date: 2025-06-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 738

Registration Number: NCT03574571

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Yale University- Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Helen Graham Cancer Center (Christiana Care), Newark, Delaware, United States

and more 67 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy